Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v8-FR
Language French French
Date Updated 2020-11-19 2020-11-19
Drug Identification Number 02258595 02258595
Brand name HUMIRA VIAL HUMIRA VIAL
Common or Proper name HUMIRA (ADALIMUMAB) VIAL HUMIRA (ADALIMUMAB) VIAL
Company Name ABBVIE CORPORATION ABBVIE CORPORATION
Ingredients ADALIMUMAB ADALIMUMAB
Strength(s) 40MG 40MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 2 x 0.8mL vial (40mg/0.8mL) 2 x 0.8mL vial (40mg/0.8mL)
ATC code L04AB L04AB
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2020-11-02 2020-11-02
Actual discontinuation date 2020-11-18 2020-11-18
Remaining supply date 2020-11-02 2020-11-02
Discontinuation status Discontinued Discontinued
Discontinuation decision reversal no no
Information on remaining supply
Company comments The HUMIRA 40mg vial will be phased out by November 2nd 2020. AbbVie has now introduced the new HUMIRA 20 mg pre-filled syringe for pediatric patients prescribed HUMIRA 20mg. HUMIRA 40mg in PEN and pre-filled syringe are still available for pediatric patients prescribed HUMIRA 40mg. The HUMIRA 40mg vial will be phased out by November 2nd 2020. AbbVie has now introduced the new HUMIRA 20 mg pre-filled syringe for pediatric patients prescribed HUMIRA 20mg. HUMIRA 40mg in PEN and pre-filled syringe are still available for pediatric patients prescribed HUMIRA 40mg.
Health Canada comments